Therapeutic delivery最新文献_第7页

Etodolac utility in osteoarthritis: drug delivery challenges, topical nanotherapeutic strategies and potential synergies. 依托度酸在骨关节炎中的应用：给药挑战、局部纳米治疗策略和潜在的协同作用。

IF 3

Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-09-30 DOI: 10.1080/20415990.2024.2405456

Pavani Gaddala, Shalki Choudhary, Sheshank Sethi, Vaskuri Gs Sainaga Jyothi, Chantibabu Katta, Deepankar Bahuguna, Pankaj Kumar Singh, Manisha Pandey, Jitender Madan

{"title":"Etodolac utility in osteoarthritis: drug delivery challenges, topical nanotherapeutic strategies and potential synergies.","authors":"Pavani Gaddala, Shalki Choudhary, Sheshank Sethi, Vaskuri Gs Sainaga Jyothi, Chantibabu Katta, Deepankar Bahuguna, Pankaj Kumar Singh, Manisha Pandey, Jitender Madan","doi":"10.1080/20415990.2024.2405456","DOIUrl":"10.1080/20415990.2024.2405456","url":null,"abstract":"Osteoarthritis (OSA) is a prevalent joint disorder characterized by losing articular cartilage, primarily affecting the hip, knee and spine joints. The impact of OSA offers a major challenge to health systems globally. Therapeutic approaches encompass surgical interventions, non-pharmacological therapies (exercise, rehabilitation, behavioral interventions) and pharmacological treatments. Inflammatory processes within OSA joints are regulated by pro-inflammatory and anti-inflammatory cytokines. Etodolac, a COX-2-selective inhibitor, is the gold standard for OSA management and uniquely does not inhibit gastric prostaglandins. This comprehensive review offers insights into OSA's pathophysiology, genetic factors and biological determinants influencing disease progression. Emphasis is placed on the pivotal role of etodolac in OSA management, supported by both preclinical and clinical evidences in topical drug delivery. Notably, in-silico docking studies suggested potential synergies between etodolac and baicalein, considering ADAMTS-4, COX-2, MMP-3 and MMP-13 as essential therapeutic targets. Integration of artificial neural network (ANN) techniques with nanotechnology approaches emerges as a promising strategy for optimizing and personalizing topical etodolac delivery. Furthermore, the synergistic potential of etodolac and baicalein warrants in-depth exploration. Hence, by embracing cutting-edge technologies like ANN and nanomedicine, the optimization of topical etodolac delivery could guide a new era of OSA treatment.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"977-995"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11583675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Industry Update: the latest developments in the field of therapeutic delivery, July 2024. 行业最新动态：2024 年 7 月治疗给药领域的最新发展。

IF 3

Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-10-18 DOI: 10.1080/20415990.2024.2414732

Peter Timmins

引用次数: 0

Solid Self Nano-Emulsifying Drug Delivery System of Dasatinib: Optimization, In-vitro, Ex-vivo and In-vivo assessment. 达沙替尼固体自纳米乳化给药系统：优化、体外、体内和体外评估。

IF 3

Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-09-17 DOI: 10.1080/20415990.2024.2397330

Mohd Aman Mohd Ateeq, Srushti Mahajan, Brojendra Nath Saren, Mayur Aalhate, Hoshiyar Singh, Essha Chatterjee, Indrani Maji, Ujala Gupta, Anitha Sriram, Santosh Kumar Guru, Pankaj Kumar Singh

{"title":"Solid Self Nano-Emulsifying Drug Delivery System of Dasatinib: Optimization, In-vitro, Ex-vivo and In-vivo assessment.","authors":"Mohd Aman Mohd Ateeq, Srushti Mahajan, Brojendra Nath Saren, Mayur Aalhate, Hoshiyar Singh, Essha Chatterjee, Indrani Maji, Ujala Gupta, Anitha Sriram, Santosh Kumar Guru, Pankaj Kumar Singh","doi":"10.1080/20415990.2024.2397330","DOIUrl":"10.1080/20415990.2024.2397330","url":null,"abstract":"Aim: Dasatinib (DST) is an oral tyrosine kinase inhibitor with poor aqueous solubility. To outwit this issue, a solid self-nano emulsifying drug delivery system (S-SNEDDS) of DST was formulated.Methods: I-optimal mixture design was used for optimization of DST-loaded SNEDDS using Linalool, Cremophor RH40 and Transcutol P. S-SNEDDS underwent physicochemical characterization, in-vitro release and ex-vivo permeation, cell-based assays and pharmacokinetic study.Results: DST-S-SNEDDS showed globule size and PDI of 141.53 ± 5.371 nm and 0.282 ± 0.020, respectively. DST-S-SNEDDS revealed significantly lower IC50 (1.825 μg/mL) than free DST (7.298 μg/mL) in MDA-MB-231. In-vivo pharmacokinetic study revealed 1.94-fold increment in AUC0-t for the DST-S-SNEDDS group than free DST.Conclusion: S-SNEDDS could be promising approach for improving bioavailability and efficacy of DST.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"749-768"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quality-by-design-based microemulsion of disulfiram for repurposing in melanoma and breast cancer therapy. 基于质量设计的双硫仑微乳剂用于黑色素瘤和乳腺癌治疗的再利用。

IF 3

Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-07-01 DOI: 10.1080/20415990.2024.2363136

Debadatta Mohapatra, Prakash Ch Senapati, Shantibhusan Senapati, Vivek Pandey, Pawan K Dubey, Sanjay Singh, Alakh N Sahu

引用次数: 0

Industry Update, May 2024. 行业最新情况，2024 年 5 月。

IF 3

Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-08-08 DOI: 10.1080/20415990.2024.2383162

Elaine Harris

引用次数: 0

Recent patents in polymer-lipid hybrid nanoparticles technology. 聚合物-脂质混合纳米粒子技术的最新专利。

IF 3

Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-07-09 DOI: 10.1080/20415990.2024.2363646

Jyoti Verma, Niraj Kumar Singh, Kuldeep K Bansal

引用次数: 0

Central composite design augmented quality-by-design-based systematic formulation of erlotinib hydrochloride-loaded chitosan-poly (lactic-co-glycolic acid) nanoparticles. 基于中央复合设计的盐酸厄洛替尼负载壳聚糖-聚（乳酸-共羟基乙酸）纳米粒子的质量改进型系统配方。

IF 3

Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-05-09 DOI: 10.1080/20415990.2024.2342771

Harsh P Nijhawan, Bala Prabhakar, Khushwant S Yadav

引用次数: 0

Synthesis and release studies on amylose-based ester prodrugs of fenamic acid NSAIDs. 基于淀粉糖的非那根酸类非甾体抗炎药酯原药的合成和释放研究。

IF 3

Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-09-17 DOI: 10.1080/20415990.2024.2400041

Shraddha Chugh, Mousmee Sharma, Garima Chandrasen, Harish Mudila, Parteek Prasher

{"title":"Synthesis and release studies on amylose-based ester prodrugs of fenamic acid NSAIDs.","authors":"Shraddha Chugh, Mousmee Sharma, Garima Chandrasen, Harish Mudila, Parteek Prasher","doi":"10.1080/20415990.2024.2400041","DOIUrl":"10.1080/20415990.2024.2400041","url":null,"abstract":"Aim: To achieve colon-targeted release of mefenamic acid from its ester-linked amylose prodrugs.Materials & methods: The prodrug was characterized by 1H NMR and IR spectroscopy. Drug activation and release profile was studied in enzyme enriched simulated physiological media via UV-vis spectroscopy and was validated with HPLC analysis. ELISA assay was employed for evaluating the % inhibition of COX-1 and COX-2 inhibition at different concentrations of the prodrug preincubated with ester and/ or amylose hydrolyzing enzymes. SEM studies further validated the performance of the prodrug under simulated physiological conditions.Results: Pancreatin was essential for the prodrug activation in SIM to make the ester bonds in prodrug vulnerable to hydrolysis by esterase. This evidence was confirmed by drug release studies, HPLC analysis, ELISA assay and SEM investigation where the ester conjugated prodrug showed marked stability in physiological media only to get activated in the presence of amylose degrading enzyme.Conclusion: Ester linked amylose-mefenamic acid conjugate showed both enzyme responsive activation and release in SIM.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"769-779"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Organic solvent-free benznidazole nanosuspension as an approach to a novel pediatric formulation for Chagas disease. 无有机溶剂苯并咪唑纳米悬浮剂作为治疗南美锥虫病的新型儿科制剂的一种方法。

IF 3

Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-08-05 DOI: 10.1080/20415990.2024.2380244

María Sol Magi, Lucía Lopez-Vidal, Mónica Cristina García, Cinthia Carolina Stempin, Constanza Marin, Belkys Maletto, Santiago Daniel Palma, Juan Pablo Real, Alvaro Federico Jimenez-Kairuz

{"title":"Organic solvent-free benznidazole nanosuspension as an approach to a novel pediatric formulation for Chagas disease.","authors":"María Sol Magi, Lucía Lopez-Vidal, Mónica Cristina García, Cinthia Carolina Stempin, Constanza Marin, Belkys Maletto, Santiago Daniel Palma, Juan Pablo Real, Alvaro Federico Jimenez-Kairuz","doi":"10.1080/20415990.2024.2380244","DOIUrl":"10.1080/20415990.2024.2380244","url":null,"abstract":"Aim: Benznidazole (BNZ), a class-II drug, is the primary treatment for Chagas disease, but its low aqueous solubility presents challenges in formulation and efficacy. Nanosuspensions (NS) could potentially address these issues.Methods: BNZ-NS were prepared using a simple, organic solvents-free nano-milling approach. Physicochemical characterizations were conducted on both NS and lyophilized solid-state BNZ-nanocrystals (NC).Results: BNZ-NS exhibited particle size <500 nm, an acceptable polydispersity index (0.23), high Z-potential, and physical stability for at least 90 days. BNZ-NC showed tenfold higher solubility than pure BNZ. Dissolution assays revealed rapid BNZ-NS dissolution. BNZ-NC demonstrated biocompatibility on an eukaryotic cell and enhanced BNZ efficacy against trypomastigotes of Trypanosoma cruzi.Conclusion: BNZ-NS offers a promising alternative, overcoming limitations associated with BNZ for optimized pharmacotherapy.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"699-716"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11415019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fabrication of dual drug-loaded polycaprolactone-gelatin composite nanofibers for full thickness diabetic wound healing. 制备用于全厚度糖尿病伤口愈合的双重药物负载聚己内酯-明胶复合纳米纤维。

IF 4.2

Therapeutic delivery Pub Date : 2023-12-21 DOI: 10.4155/tde-2023-0083

Manjit Manjit, Manish Kumar, Krishan Kumar, Madhukiran R Dhondale, Abhishek Jha, Kanchan Bharti, Zinnu Rain, Pradyot Prakash, Brahmeshwar Mishra

引用次数: 0